I have bloating, stomach discomfort, sour stomach, and dizziness despite being diagnosed with gastroesophageal reflux disease (GERD), hiatal hernia, and stage 1 Barrett’s esophagus, and having taken vonoprazan (voquezna) for six months with occasional flare‑ups and intermittent Gaviscon (alginate) use; what management steps should I take?

Management of Persistent GERD Symptoms Despite Vonoprazan Therapy

Continue vonoprazan (Voquezna) at your current dose and schedule an upper endoscopy to evaluate for inadequate healing, complications, or alternative diagnoses, while optimizing lifestyle modifications and considering diagnostic testing if symptoms persist after endoscopic evaluation.

Immediate Assessment and Optimization

Your situation—persistent bloating, stomach discomfort, sour stomach, and dizziness after 6 months of vonoprazan therapy for GERD, hiatal hernia, and stage 1 Barrett's esophagus—requires systematic evaluation rather than simple medication adjustment.

Continue Current Acid Suppression

Do not discontinue vonoprazan. With documented Barrett's esophagus, continuous acid suppression is essential 1, 2. The FDA label for vonoprazan (Voquezna) approves maintenance therapy for up to 6 months for erosive esophagitis 3, and you are at that threshold. However, Barrett's esophagus requires ongoing acid suppression to prevent progression 1.

Endoscopic Evaluation is Critical

Schedule upper endoscopy with your gastroenterologist. Given your Barrett's esophagus diagnosis and persistent symptoms despite 6 months of potent acid suppression, endoscopy is indicated to:

• Assess healing status of any erosive esophagitis
• Evaluate Barrett's segment for dysplasia progression (you should be on surveillance anyway with stage 1 Barrett's) 4, 2
• Document hiatal hernia size and Hill grade 5
• Rule out complications like stricture or eosinophilic esophagitis 6
• Exclude alternative diagnoses causing your symptoms 7

Important caveat: The 2024 NICE guidelines recommend surveillance endoscopy for Barrett's esophagus at intervals based on segment length and dysplasia status 2. With stage 1 Barrett's (assuming this means non-dysplastic), you should have surveillance every 3-5 years, but your persistent symptoms warrant evaluation sooner 4, 2.

Understanding Your Symptoms

Your symptom profile—bloating, stomach discomfort, and dizziness—may not all stem from acid reflux:

Bloating and Stomach Discomfort

These symptoms are common side effects of vonoprazan itself. The FDA label lists "stomach bloating," "stomach pain," "nausea," and "indigestion" as the most common adverse effects 3. This creates a diagnostic challenge: are your symptoms from inadequate GERD control or medication side effects?

Consider food intolerances. Bloating specifically may indicate carbohydrate malabsorption (lactose, fructose, FODMAPs) or small intestinal bacterial overgrowth, which can coexist with GERD 8. A 2-week trial eliminating common triggers (dairy, high-fructose foods, artificial sweeteners) may clarify this 8.

Dizziness

This is not a typical GERD symptom and warrants separate evaluation. Potential causes include:

• Medication side effect (though not commonly reported with vonoprazan)
• Dehydration from diarrhea (another vonoprazan side effect 3)
• Anemia from chronic blood loss (if erosive esophagitis is severe)
• Unrelated cardiovascular or neurologic issues

Optimizing Your Current Regimen

Lifestyle Modifications (Grade A Recommendation)

The 2008 AGA guidelines strongly recommend lifestyle modifications for GERD 6. Specifically:

• Elevate head of bed 6-8 inches (not just pillows—entire bed frame)
• Avoid eating within 3 hours of bedtime
• Weight loss if BMI >25 (even 5-10% reduction helps)
• Avoid trigger foods: chocolate, caffeine, alcohol, peppermint, fatty/fried foods, acidic foods
• Smoking cessation if applicable

Gaviscon Use

Your intermittent Gaviscon use is appropriate for breakthrough symptoms. Gaviscon (alginate-based) creates a physical barrier and can be used as needed with vonoprazan 1.

Diagnostic Testing if Symptoms Persist

If endoscopy shows adequate healing but symptoms continue, consider:

High-Resolution Manometry (HRM)

Recommended to evaluate for:

• Esophageal motor disorders that mimic GERD 6, 7
• Ineffective esophageal motility contributing to reflux
• Behavioral disorders (rumination, supragastric belching causing bloating) 8

pH-Impedance Monitoring While ON Vonoprazan

This is the gold standard for refractory symptoms 6, 7. It distinguishes:

• True refractory GERD: Persistent acid exposure despite medication (acid exposure time >4%)
• Non-acid reflux: Excessive reflux events that aren't acidic
• Functional heartburn: Normal reflux parameters with symptom hypersensitivity

Recent research shows that patients with hiatal hernia have significantly higher recurrence rates and may need more aggressive management 9. Your hiatal hernia is a key factor here.

Treatment Adjustments Based on Findings

If Endoscopy Shows Inadequate Healing

Option 1: Increase vonoprazan to twice-daily dosing (20 mg twice daily). While the FDA label approves once-daily dosing 3, twice-daily PPI dosing is standard for refractory cases 6, and vonoprazan's mechanism suggests similar benefit.

Option 2: Consider switching to high-dose PPI twice daily if vonoprazan side effects are contributing to symptoms.

If Endoscopy Shows Adequate Healing But Symptoms Persist

This suggests either:

1. Non-acid reflux (needs pH-impedance testing 7)
2. Functional overlay (visceral hypersensitivity)
3. Alternative diagnosis (eosinophilic esophagitis, gastroparesis, functional dyspepsia)

Role of Hiatal Hernia

Your hiatal hernia is significant. Research shows that hiatal hernia presence is the strongest predictor of symptom recurrence after stopping acid suppression 9. The 2025 ASGE guidelines recommend:

• Small hiatal hernias (≤2 cm) with Hill grade I-II: Consider transoral incisionless fundoplication (TIF) if symptoms persist despite optimal medical therapy 5
• Large hiatal hernias (>2 cm) with Hill grade III-IV: Consider combined TIF with hiatal hernia repair (cTIF) or surgical fundoplication 5

However, anti-reflux surgery is NOT recommended solely for Barrett's esophagus prevention 6. It should only be considered for symptom control when medical therapy fails.

Barrett's Esophagus Surveillance

Critical point: With stage 1 Barrett's esophagus, you need regular surveillance regardless of symptoms:

• Non-dysplastic Barrett's: Endoscopy every 3-5 years (depending on segment length) 2
• Low-grade dysplasia: Endoscopy every 6 months initially, then annually if confirmed by expert GI pathologist 4
• High-grade dysplasia: Endoscopic resection and ablation 2

Your endoscopist should use high-definition white-light endoscopy with Seattle protocol biopsies (4-quadrant biopsies every 1-2 cm) 4, 2.

Common Pitfalls to Avoid

1. Don't stop vonoprazan without gastroenterologist guidance. Barrett's esophagus requires continuous acid suppression 1.

2. Don't assume all symptoms are from GERD. Bloating and dizziness may have other causes 8, 7.

3. Don't delay endoscopy. With Barrett's esophagus and persistent symptoms, endoscopic evaluation is essential 4, 2.

4. Don't ignore medication side effects. Vonoprazan itself can cause bloating and GI discomfort 3.

5. Don't pursue anti-reflux surgery without proper diagnostic workup. Surgery requires objective evidence of reflux on pH testing and assessment of esophageal motility 6, 5.

Specific Next Steps

1. Schedule upper endoscopy with high-definition equipment and Seattle protocol biopsies for Barrett's surveillance
2. Continue vonoprazan 20 mg daily until endoscopy results guide next steps
3. Implement strict lifestyle modifications (head elevation, dietary changes, meal timing)
4. Trial 2-week elimination diet for bloating (remove dairy, high-fructose foods, artificial sweeteners)
5. Document symptom patterns (timing, triggers, severity) to guide diagnostic testing
6. Evaluate dizziness separately if it persists (check orthostatic vitals, complete blood count)

Long-Term Considerations

Vonoprazan has been approved for maintenance therapy up to 6 months 3, but you have Barrett's esophagus requiring indefinite acid suppression 1. The 2008 AGA guidelines note that chronic PPI therapy is required for most GERD patients and that the main risk of stopping therapy is symptom recurrence, not disease progression 6. However, Barrett's esophagus changes this calculus—you need ongoing suppression.

The decision about long-term vonoprazan vs. switching to PPI should be made with your gastroenterologist based on:

• Endoscopic findings
• Symptom response
• Side effect profile
• Cost considerations (vonoprazan is significantly more expensive than generic PPIs)

Recent 2024 AGA guidance suggests vonoprazan may be particularly useful in PPI-refractory cases 10, but if you're having side effects, a high-quality PPI twice daily may be equally effective and better tolerated.